| P/E (FY) | — | Sales (TTM) | $1.08B |
| Earnings (TTM) | -$433.2M | ROE | — |
| Net Margin | −42.39% | ROIC | −45.94% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 29.75% |
Guardant Health is a precision oncology company providing blood and tissue tests and data sets in the United States and internationally. Its products include the Guardant360 CDx and Liquid tests for tumor mutation profiling, the Guardant Reveal blood test using circulating tumor DNA, the Guardant360 Tissue molecular profiling test, and the Shield blood test for colorectal cancer screening. It also offers the GuardantINFINITY and GuardantOMNI tests for cancer research and therapy development.
| Market Cap | $19.04B | Trading Days | 1959 |
| 52W High | 174.08 |
| 52W Low | 40.35 |
| % Off High | −17.50% |
| YTD | 40.61% | 1Y | 224.42% |
| 3Y | 269.96% | 5Y | 27.98% |
| Since incept. (ann.) | 21.09% |
Reportable 100%
| Ann. Volatility (1Y) | 60.88% | Ann. Volatility (3Y) | 62.46% |
| Sharpe (1Y) | 2.26 | Sharpe (3Y) | 1.03 |
| Max Drawdown (1Y) | −32.98% | Max Drawdown (3Y) | −59.79% |
| Beta (3Y, vs SPY) | 2.04 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LH | LABCORP HOLDINGS INC. | $25.77B | 30.0 |
| DGX | QUEST DIAGNOSTICS INC | $26.04B | 27.0 |
| NTRA | Natera, Inc. | $36.12B | — |
| RDNT | RadNet, Inc. | $4.97B | — |
| VCYT | VERACYTE, INC. | $4.44B | 67.9 |
| CAI | Caris Life Sciences, Inc. | $4.41B | — |
| CELC | Celcuity Inc. | $4.02B | — |
| BLLN | BillionToOne, Inc. | $2.84B | 380.6 |
| GRAL | GRAIL, Inc. | $2.76B | — |
| FTRE | Fortrea Holdings Inc. | $1.96B | — |
| CDNA | CareDx, Inc. | $1.85B | — |
| PSNL | Personalis, Inc. | $1.24B |
| — |
